A preclinical study reveals that the combination regimen of chidamide (a novel orally active HDAC inhibitor) and IDA could rapidly diminish the tumor burden in patients with refractory or relapsed AML (Li et al., 2017). This evidence concerns the gene HDAC9 and acute myeloid leukemia.